Scale-Up of an Human Papillomavirus Testing Implementation Program in El Salvador

Journal of Lower Genital Tract Disease

Volumn 21, Issue 1, 2017, Pages 26-32

  Cremer, Miriam ^a,b   Maza, Mauricio ^b   Alfaro, Karla ^b   Morales Velado, Mario ^c   Felix, Juan ^d   Castle, Philip E ^e,f   Kim, Jane ^g,h   Gage, Julia C ^d  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^b Basic Health International   (El Salvador)

^c Ministry of Health   (El Salvador)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^g Global Coalition Against Cervical Cancer   (United States)

^h HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

cervical cancer; human papillomavirus; screening and care of human papillomavirus

Indexed keywords

ADULT; COLPOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOTHERAPY; DIAGNOSIS; DOCTOR PATIENT RELATION; EL SALVADOR; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NONHUMAN; PHASE 2 CLINICAL TRIAL; PREGNANCY; SAMPLING; SCALE UP; SCREENING; WART VIRUS; COHORT ANALYSIS; EARLY CANCER DIAGNOSIS; HEALTH SERVICE; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; UTERINE CERVICAL NEOPLASMS;

ADULT; COHORT STUDIES; EARLY DETECTION OF CANCER; EL SALVADOR; FEMALE; HEALTH SERVICES ADMINISTRATION; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 85002292065     PISSN: 10892591     EISSN: 15260976     Source Type: Journal    
DOI: 10.1097/LGT.0000000000000280     Document Type: Article

References (20)

1. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer; 2013.
2. WHO Guidelines Approved by the Guidelines Review Committee. WHO Guidelines for Screening and Treatment of Precancerous Lesions for Cervical Cancer Prevention. Geneva: World Health Organization; 2013.
3. Goldie SJ, Kuhn L, Denny L, et al. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA 2001;285:3107-15.
4. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, et al. Cost-effectiveness of cervical-cancer screening in five developing countries.NEngl JMed 2005; 353:2158-68
5. Campos NG, Maza M, Alfaro K, et al. The comparative and cost-effectiveness of HPV-based cervical cancer screening algorithms in El Salvador. Int J Cancer 2015;137:893-902.
6. Bansil P, Wittet S, Lim JL, et al. Acceptability of self-collection sampling for HPV-DNA testing in low-resource settings: a mixed methods approach. BMC Public Health 2014;14:596.
7. Lorenzi AT, Fregnani JH, Possati-Resende JC, et al. Self-collection for high-risk HPV detection in Brazilian women using the careHPV™ test. Gynecol Oncol 2013;131:131-4.
8. Campos NG, Castle PE, Wright TC Jr, et al. Cervical cancer screening in low-resource settings: a cost-effectiveness framework for valuing tradeoffs between test performance and program coverage. Int J Cancer 2015;137: 2208-19.
9. Denny L, Kuhn L, De Souza M, et al. Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. JAMA 2005;294:2173-81.
10. Denny L, Kuhn L, Hu CC, et al. Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial. J Natl Cancer Inst 2010;102:1557-67.
11. CremerML, Maza M, AlfaroKM, et al. Introducing a high-risk HPV DNA test into a public sector screening program in El Salvador. J Low Genit Tract Dis 2016;20:145-50.
12. Rosenbaum AJ, Gage JC, Alfaro KM, et al. Acceptability of self-collected versus provider-collected sampling for HPV DNA testing among women in rural El Salvador. Int J Gynaecol Obstet 2014;126:156-60.
13. Agurto I, Sandoval J, De La Rosa M, et al. Improving cervical cancer prevention in a developing country. Int J Qual Health Care 2006;18:81-6.
14. Bruni L B-RL, Albero G, Aldea M, et al. Human papillomavirus and related diseases in El Salvador. Summary Report. ICO Information Centre on HPVand Cancer (HPV Information Centre); 2015.
15. Jacob M, Broekhuizen FF, Castro W, et al. Experience using cryotherapy for treatment of cervical precancerous lesions in low-resource settings. Int J Gynaecol Obstet 2005;89(suppl 2):S13-20.
16. McClung EC, Blumenthal PD. Efficacy, safety, acceptability and affordability of cryotherapy: a reviewof current literature. Minerva Ginecol 2012;64:149-71.
17. Mitchell MF, Tortolero-Luna G, Cook E, et al. A randomized clinical trial of cryotherapy, laser vaporization, and loop electrosurgical excision for treatment of squamous intraepithelial lesions of the cervix. Obstet Gynecol 1998;92:737-44.
18. Chirenje ZM, Rusakaniko S, Akino V, et al. A randomised clinical trial of loop electrosurgical excision procedure (LEEP) versus cryotherapy in the treatment of cervical intraepithelial neoplasia. J Obstet Gynaecol 2001;21: 617-21.
19. Dalla Palma P, Giorgi Rossi P, Collina G, et al. The reproducibility of CIN diagnoses among different pathologists: data from histology reviews from a multicenter randomized study. Am J Clin Pathol 2009;132: 125-32.
20. Stoler MH, Schiffman M, Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSILTriage Study. JAMA 2001;285:1500-5.